Farxiga

E505482

Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.

All labels observed (1)

Label Occurrences
Farxiga canonical 2

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf SGLT2 inhibitor ⓘ
antihyperglycemic agent ⓘ
brand name drug ⓘ
prescription medication ⓘ
approvalYear 2014 ⓘ
approvedBy European Medicines Agency ⓘ
U.S. Food and Drug Administration ⓘ
ATCCode A10BK01 ⓘ
combinationTherapy may be used with insulin ⓘ
may be used with metformin ⓘ
may be used with other oral antidiabetic agents ⓘ
contraindication patients with a history of serious hypersensitivity to dapagliflozin ⓘ
developer AstraZeneca ⓘ
doesNotTreat type 1 diabetes mellitus ⓘ
dosageForm tablet ⓘ
effect induces osmotic diuresis ⓘ
lowers blood glucose levels ⓘ
may reduce body weight ⓘ
may reduce systolic blood pressure ⓘ
FDAApprovalStatus approved ⓘ
hasActiveIngredient dapagliflozin ⓘ
indication improve glycemic control in adults with type 2 diabetes ⓘ
reduce risk of cardiovascular death and hospitalization for heart failure in adults with heart failure ⓘ
reduce risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors ⓘ
reduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease ⓘ
treatment of chronic kidney disease in adults ⓘ
lactationUse caution advised ⓘ
marketingAuthorizationHolder AstraZeneca ⓘ
mechanismOfAction increases urinary glucose excretion ⓘ
inhibits SGLT2 in the proximal renal tubules ⓘ
reduces reabsorption of filtered glucose in the kidney ⓘ
monitoringParameter blood glucose ⓘ
renal function ⓘ
signs and symptoms of ketoacidosis ⓘ
volume status ⓘ
pharmacologicClass sodium-glucose cotransporter 2 inhibitor ⓘ
pregnancyCategory use only if potential benefit justifies potential risk ⓘ
risk acute kidney injury ⓘ
genital mycotic infections ⓘ
hypotension ⓘ
ketoacidosis ⓘ
urinary tract infections ⓘ
volume depletion ⓘ
routeOfAdministration oral ⓘ
takenWithOrWithoutFood true ⓘ
treats type 2 diabetes mellitus ⓘ
typicalDose 10 mg once daily ⓘ
5 mg once daily ⓘ
warning not recommended in patients with severe renal impairment, end-stage renal disease, or on dialysis ⓘ

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

AstraZeneca → notableProduct → Farxiga ⓘ
AstraZeneca plc → famousForProduct → Farxiga ⓘ
subject linked to: AZN